bcl6 degrader bms-986458
Generic: BCL6 Degrader BMS-986458
bcl6 degrader bms-986458: 1 clinical trial tracked.
bcl6 degrader bms-986458 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about bcl6 degrader bms-986458, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Primary endpoint: Number of participants with adverse events (AEs)
InterventionalRandomizedopen460 targetStarted 2023-12Completion 2028-1050 sites · Chile, China, France, Germany…Bristol-Myers Squibb